Glioma Market Research Report-Size, Share, Growth, and Trend Analysis | Forecast (2022 - 2032)
The glioma market pertains to the therapeutic and diagnostic landscape for gliomas, a diverse group of brain and spinal cord tumors originating from glial cells. Gliomas are characterized by their high malignancy, with glioblastoma multiforme (GBM) being the most aggressive form. Treatment strategies are evolving with the introduction of targeted therapies, immunotherapies, and novel surgical techniques. The market includes various types of gliomas such as glioblastomas, astrocytomas, and oligodendrogliomas, with a focus on improving survival rates and quality of life for patients.
Disruptive Impact and Opportunities:
The glioma market presents significant opportunities for innovation and disruption, particularly in the development of targeted therapies and immunotherapies. New treatments offer the potential to not only extend survival but also enhance the effectiveness of existing therapies. As patients with glioma, especially GBM, have limited treatment options, novel therapies addressing both the tumor microenvironment and genetic mutations present big opportunities. New technologies like gene therapy and personalized medicine are poised to drive market growth, simplifying treatment regimens, improving efficacy, and ensuring safety with fewer side effects. These trends reflect a shift towards safer, more targeted, and effective treatments in a market characterized by high unmet medical needs.
Emerging Drugs:
- Ofranergene obadenovec (VB-111)
- SurVaxM
- Vorasidenib (AG-881)
- Tovorafenib (DAY101)
Marketed Drugs:
- AVASTIN
- TEMODAR (temozolomide)
Key Companies:
- Bayer
- Chimerix
- Aivita Biomedical
- Denovo Biopharma
- Northwest Therapeutics
- VBL Therapeutics
- Laminar Pharmaceuticals
- MedImmune
- DNAtrix
Market Segmentation:
By Type
- Glioblastoma Multiforme (GBM)
- Anaplastic Astrocytoma
- Oligodendroglioma
- Ependymoma
- Pilocytic Astrocytoma
- Other Gliomas
By Administration Type
· Oral Administration
- Small Molecule Drugs
- Targeted Therapy
- Chemotherapeutic Agents
· Parenteral Administration
- Intravenous (IV)
- Intratumoral
- Subcutaneous (SC)
· Intracerebral Administration
- Implantable Devices
- Convection-Enhanced Delivery
- Gene Therapy
What’s in It for You?
- Identification of key emerging therapies and potential disruptors
- Insight into the competitive landscape and strategies of leading companies
- Opportunities to align investment strategies with high-growth sectors within glioma treatment
- Evaluation of market dynamics and trends to capitalize on new treatment methodologies
- Data-driven approach to understanding patient needs and the evolving regulatory environment
Glioma Market Analysis (Market Size & CAGR, Epidemiology, Marketed Therapies, Emerging Drugs, Clinical Trials, Key Approvals & Anticipated Loss of Exclusivity, Opportunities, Unmet Needs, Company Profiles)
1. Glioma Market - Executive Summary
1.1. Introduction
1.2. Objectives
1.3. Key Findings
1.3.1. Market Size 2025 & 2030: By Key Country (10MM)
1.3.2. Global Market Size 2025 & 2030:By Key Segment
1.3.3. Key Investments & Startup Analysis
1.4. Research Methodology
2. Understanding the Disease
2.1. Disease Overview
2.2. Classification
2.3. Signs and Symptoms
2.4. Risk Factors
2.5. Causes
2.6. Disease Biology & Digital Innovations
2.7. Stages & Staging System
2.8. Diagnostic Algorithm
2.9. Current Treatment Practices & Algorithm
2.10. Current Standard of Care and Treatment Gaps
2.11. Patient Demographics and Treatment Pathways
3. Guidelines
4. Unmet Needs
5. Epidemiology and Patient Population
5.1. Epidemiology Key Findings
5.2. Assumptions and Rationale: 10MM
5.3. Epidemiology Scenario: 10MM
5.4. U.S. Epidemiology Scenario
5.5. EU-5 Epidemiology
5.5.1. U.K. Epidemiology Scenario
5.5.2. Germany Epidemiology Scenario
5.5.3. France Epidemiology Scenario
5.5.4. Italy Epidemiology Scenario
5.5.5. Spain Epidemiology Scenario
5.6. Japan Epidemiology Scenario
5.7. China Epidemiology Scenario
5.8. Australia Epidemiology Scenario
5.9. India Epidemiology Scenario
6. Real-world Data & Real-world Evidence
7. Drug Development Landscape
7.1. Existing Key Drug Candidate Profiles/ Marketed Therapies
7.1.1. AVASTIN
7.1.1.1. Product Description
7.1.1.2. Regulatory Milestones
7.1.1.3. Other Developmental Activities
7.1.1.4. Pivotal Clinical Trials
7.1.1.5. Ongoing Current Pipeline Activity
7.1.2. TEMODAR (temozolomide)
7.1.2.1. Product Description
7.1.2.2. Regulatory Milestones
7.1.2.3. Other Developmental Activities
7.1.2.4. Pivotal Clinical Trials
7.1.2.5. Ongoing Current Pipeline Activity
7.2. Competitive Analysis and Differentiation
7.3. Overview of Similar/Competing Drugs in Clinical Trials
7.4. Future Trends and Emerging Drugs
7.4.1. Ofranergene obadenovec (VB-111)
7.4.1.1. Product Description
7.4.1.2. Clinical Development
7.4.1.3. Safety and Efficacy
7.4.2. SurVaxM
7.4.2.1. Product Description
7.4.2.2. Clinical Development
7.4.2.3. Safety and Efficacy
7.4.3. Vorasidenib (AG-881)
7.4.3.1. Product Description
7.4.3.2. Clinical Development
7.4.3.3. Safety and Efficacy
7.4.4. Tovorafenib (DAY101)
7.4.4.1. Product Description
7.4.4.2. Clinical Development
7.4.4.3. Safety and Efficacy
8. Regulatory Strategy and Potential Challenges
8.1. Regulatory Pathways in Key Markets
8.2. Anticipated Regulatory Hurdles and Mitigation Strategies
8.3. Case Studies in Oncology Drug Regulation
8.4. Impact of Potential Changes to Regulatory Framework
9. Commercial Landscape
9.1. Market Size & Growth Rates
9.2. Key Approvals & Anticipated Loss of Exclusivity
9.3. PESTLE & Porter’s Five Forces Analysis
9.4. Market Shares, Positioning/Ranking
9.5. Market Drivers
9.6. Identification of Threats
9.7. Digital Evolution in Commercialization
10. Market Segmentation
10.1. Market by Therapy Type
10.1.1. Chemotherapy
10.1.2. Targeted Therapy
10.1.3. Immunotherapy
10.1.4. Surgery
10.1.5. Others
10.2. Market by Type
10.2.1. Low-Grade
10.2.2. High-Grade
11. Pricing, Reimbursement, and Access
11.1. Competitive Pricing Analysis
11.2. Reimbursement Landscape and Challenges
11.3. Strategies for Market Access and Equity
11.4. Patient Spending/Expenditure Analysis
12. Future Trends, Disruptions, and Opportunities
12.1. Analysis of Emerging Trends
12.2. Technological Impact
12.3. Impact of Potential Market Disruptors
12.4. Opportunities for Future Development and Expansion
12.5. Considerations for Investment Opportunities
13. Global Market Dynamics
13.1. Regional Regulatory Disparities
13.2. Cross-Border Partnership Strategies
13.3. Global Supply Chain Dynamics
13.4. Case Studies: Success and Failure in Global Markets
13.5. Strategies for Global Expansion and Localization
14. Company Profiles
14.1. Bayer
14.2. Bristol Myers Squibb
14.3. Medicenna Therapeutics
14.4. BioMimetix
14.5. Merck
14.6. Eli Lilly
14.7. Hoffmann-La Roche
14.8. Incyte Corporation
14.9. Kazia Therapeutics
14.10. Genenta Science
Download Sample
Choose License Type
2500
4250
5250
6900
